Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28063734)

Published in Am J Kidney Dis on January 04, 2017

Authors

Wolfgang C Winkelmayer1, Benjamin A Goldstein2, Aya A Mitani3, Victoria Y Ding4, Medha Airy5, Sreedhar Mandayam5, Tara I Chang6, M Alan Brookhart7, Steven Fishbane8

Author Affiliations

1: Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX. Electronic address: winkelma@bcm.edu.
2: Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC.
3: Department of Biostatistics, Boston University School of Public Health, Boston, MA.
4: Center for Biomedical Informatics Research, Stanford University School of Medicine, Palo Alto, CA.
5: Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX.
6: Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA.
7: Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC.
8: Division of Kidney Diseases and Hypertension, Hofstra Northwell School of Medicine, Great Neck, NY.

Articles cited by this

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med (2009) 8.25

Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57

Validating administrative data in stroke research. Stroke (2002) 5.90

Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int (2014) 3.04

Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products. JAMA (2015) 2.35

Addressing missing data in clinical studies of kidney diseases. Clin J Am Soc Nephrol (2014) 2.23

Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol (2013) 2.06

Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol (2004) 1.51

Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol (2012) 1.27

Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant (2000) 1.25

The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle. Am J Kidney Dis (2013) 1.12

Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients. Clin Nephrol (2006) 1.06

Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int (2016) 1.00

An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol (1997) 0.97

Receipt of Intravenous Iron and Clinical Outcomes among Hemodialysis Patients Hospitalized for Infection. Clin J Am Soc Nephrol (2015) 0.92

Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients. Am J Kidney Dis (2015) 0.83

Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis (2015) 0.82

Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients. Nephrol Dial Transplant (2015) 0.82